Literature DB >> 16285355

Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infections.

M H Wilcox1.   

Abstract

Treatment of complicated skin and skin structure infection (cSSSI) and complicated intra-abdominal infection (cIAI) currently present a therapeutic challenge because many of the pathogens involved are becoming resistant to standard antimicrobial therapy. Tigecycline is a novel glycylcycline that exhibits expanded broad-spectrum antibacterial activity against certain resistant pathogens. Results from randomised Phase III studies comparing the clinical and microbiological efficacy of tigecycline with combination antimicrobial therapy for the treatment of cSSSI and cIAI are encouraging. Tigecycline has the potential to be used as monotherapy for the treatment of cSSSI and cIAI.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16285355     DOI： 10.1179/joc.2005.17.Supplement-1.23

Source DB:  PubMed          Journal:  J Chemother        ISSN： 1120-009X            Impact factor:   1.714


  6 in total

1.  Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.

Authors:  Christopher M Rubino; Lei Ma; Sujata M Bhavnani; Joan Korth-Bradley; John Speth; Evelyn Ellis-Grosse; Keith R Rodvold; Paul G Ambrose; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

2.  In vitro activity of ten antibiotics, including tigecycline, against Bacteroides species in Austria.

Authors:  A J Grisold; I Wendelin; E Presterl; R B Raggam; L Masoud; A Badura; E Marth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-07       Impact factor: 3.267

3.  Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.

Authors:  A K Meagher; J A Passarell; B B Cirincione; S A Van Wart; K Liolios; T Babinchak; E J Ellis-Grosse; P G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

4.  Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.

Authors:  J A Passarell; A K Meagher; K Liolios; B B Cirincione; S A Van Wart; T Babinchak; E J Ellis-Grosse; P G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

5.  Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection.

Authors:  Christine M Bassis; Casey M Theriot; Vincent B Young
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

6.  Meropenem in the treatment of complicated skin and soft tissue infections.

Authors:  Douglas N Fish
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.